1. Home
  2. GNLN vs BLRX Comparison

GNLN vs BLRX Comparison

Compare GNLN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenlane Holdings Inc.

GNLN

Greenlane Holdings Inc.

HOLD

Current Price

$0.75

Market Cap

13.2M

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.81

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLN
BLRX
Founded
2005
2003
Country
United States
Employees
N/A
N/A
Industry
Durable Goods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
12.6M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
GNLN
BLRX
Price
$0.75
$2.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
231.6K
13.5K
Earning Date
02-22-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,275,000.00
N/A
Revenue This Year
$1,541.21
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$2.30
52 Week High
$7.73
$7.77

Technical Indicators

Market Signals
Indicator
GNLN
BLRX
Relative Strength Index (RSI) 16.87 40.88
Support Level $0.77 $2.79
Resistance Level $0.91 $3.08
Average True Range (ATR) 0.14 0.16
MACD -0.01 -0.02
Stochastic Oscillator 8.28 7.25

Price Performance

Historical Comparison
GNLN
BLRX

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: